预约演示
更新于：2026-05-19
Galantamine Hydrobromide
氢溴酸加兰他敏
更新于：2026-05-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 瑞典 (2000-11-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H22BrNO3 |
InChIKeyQORVDGQLPPAFRS-XPSHAMGMSA-N |
CAS号1953-04-4 |
关联
128
项与 氢溴酸加兰他敏 相关的临床试验NCT07003386
Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke Based on the Neurovascular Unit
CTR20253220
评估受试制剂氢溴酸加兰他敏片（规格： 4 mg）与参比制剂レミニール®（ 规格： 4 mg）在健康成年参与者空腹状态下的单中心、随机、开放、单剂量、两周期、两序列、交叉生物等效性试验
CTR20252254
评估受试制剂氢溴酸加兰他敏片（规格： 4 mg）与参比制剂レミニール®（ 规格： 4 mg）在健康成年参与者餐后状态下的单中心、随机、开放、单剂量、两周期、两序列、交叉生物等效性试验
100 项与 氢溴酸加兰他敏 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸加兰他敏 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸加兰他敏 相关的专利（医药）
登录后查看更多信息
2,762
项与 氢溴酸加兰他敏 相关的文献（医药）2026-12-01JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
Ligand and structure-based toxicological assessment of (thio)semicarbazones on cholinesterases
Article
作者: da Silva Mendes, Francisco Rogênio ; Belarmino, Anthony Barbosa ; Roberto, Caio Henrique Alexandre ; de Lima-Neto, Pedro ; Gomes, Akenaton Onassis Cardoso Viana ; de Sousa, Damião Sampaio ; Marinho, Márcia Machado ; Marinho, Gabrielle Silva
Abstract:
Thiosemicarbazones (TSCBZ) are promising insecticidal compounds, but their potential neurotoxicity remains unclear. This study aimed to evaluate the toxicity and cholinesterase inhibition of six substituted TSCBZ derivatives using ligand- and structure-based computational approaches. Electronic property analysis revealed that bromine substitution enhances electrophilicity, while sulfur (in TSCBZ1–3) and nitrogen (in TSCBZ4–6) are the most nucleophilic sites. Toxicity prediction indicated that TSCBZ1, 4, and 6 may induce acute and chronic effects in aquatic organisms. Molecular docking showed that TSCBZ1 and TSCBZ4 exhibit higher affinity for acetylcholinesterase than galantamine, suggesting potential selective inhibition. These findings provide novel insights into the structure–toxicity relationship of TSCBZ and their environmental safety profile.
2026-08-01BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Novel 2-aminopyrimidine carboxamide derivatives as potential anti-Alzheimer's disease agents: Design, synthesis, biological activity and computational simulation evaluation
Article
作者: Zhang, Chao-Yue ; Ma, Zheng-Yue ; Qin, Shi-Hao ; Du, Wen-Rong ; Wang, Yi-Xuan ; Zhou, Xue-Wei
In this study, a series of 2-amino-5-formamidopyrimidine derivatives were designed and synthesized. Their potential as cholinesterase inhibitors (ChEIs) for the treatment of Alzheimer's disease (AD) were evaluated by the Ellman method. Meanwhile, the antioxidant activity of these compounds were assessed by the DPPH (2,2-diphen-yl-1-picrylhydrazyl) free radical scavenging assay. The cholinesterase (ChE) inhibition test showed that most compounds exhibited excellent to moderate inhibitory effects on acetylcholinesterase (AChE), while most of them did not show significant inhibitory effects on butyrylcholinesterase (BuChE), demonstrating significant selectivity. Among them, compound 9 s (AChE: IC50 = 1.60 μM) whose AChE inhibitory activity is superior to the positive control galantamine (AChE: IC50 = 5.10 μM) is the most promising representative compound. Meanwhile, compound 9 s has high selectivity with a SI (IC50 ratio of BuChE to AChE) value of 29.85. The results of enzyme kinetics study determined that compound 9 s was a mixed-type inhibitor. Additionally, the molecular docking studies results indicated that compound 9 s could simultaneously interact with the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE, which was consistent with the results of the enzyme kinetics experiments. Molecular dynamics (MD) simulation study further verified the stability of the 9 s-AChE complex. In addition, the DPPH radical scavenging assay indicated that these compounds also possessed relatively weak antioxidant activities. Among them, compound 9p exhibited the best antioxidant activity with an IC50 value of 113.93 μM, which was lower than that of the positive control ascorbic acid (IC50 = 41.17 μM). Overall, these experimental results suggested that compound 9 s as AChE inhibitor had potential value for further research.
2026-07-01TALANTA
From biosensing to herbal discovery: A nanozyme cascade platform for acetylcholinesterase monitoring and inhibitor screening in synthetic and natural sources
Article
作者: Qin, Jia ; Cai, Shuang ; Wu, Cong-Ting ; Li, Jing ; Qin, Ya-Jian ; Xu, Wen ; Fan, Bao-Wen ; Pu, Cheng-Yang
Early diagnosis and therapeutic intervention for Alzheimer's disease (AD) necessitate advanced tools for detecting acetylcholinesterase (AChE) activity and screening AChE inhibitors (AChEIs). This study developed a novel bimetallic MOF nanozyme, Cu-NH2-88B(Fe), exhibiting significant peroxidase-like activity. This nanozyme was integrated with AChE to construct a dual-enzyme cascade biosensing platform, which achieved highly sensitive AChE detection, with a detection limit of 0.01 mU/mL, and demonstrated excellent accuracy in fetal bovine serum (spiked recoveries: 92.07-111.09%). Additionally, the platform also enabled quantitative assessment of synthetic AChEIs, determining IC50 values for donepezil (9.85 nM), neostigmine (1.41 μM), huperzine A (6.21 μM), and galantamine (611.31 μM), all of which exhibited broad linear ranges and high sensitivity. All four compounds exhibited a broad linear range and excellent sensitivity. Innovatively, the platform was applied to screen AChE inhibitory activity in seven traditional Chinese medicines (TCMs). Crucially, when comparing four extraction methods, ultrasound-assisted extraction (UAE) proved most effective in liberating active compounds. The UAE-obtained extract of Poria cocos (Yunnan) showed the strongest inhibition, achieving an AChE inhibition rate of 39.03% at 0.01 mg/mL. Notably, the screening results across different species, origins, and extraction methods (including the superior UAE) showed high consistency with the classical Ellman method, validating the platform's reliability. This study not only provides a low-cost, easy-to-operate, sensitive, and reliable analytical strategy for AChE activity detection and AChE inhibitor development, but more importantly, it successfully applies nanozyme technology to the complex system of TCMs, offering strong technical support for the screening and preliminary identification of potential anti-AD active components from TCM resources.
100 项与 氢溴酸加兰他敏 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 美国 | 2001-02-28 | |
| 痴呆 | 美国 | 2001-02-28 | |
| 阿尔茨海默病引起的痴呆症 | 瑞典 | 2000-11-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 精神分裂症 | 临床3期 | - | 2003-03-01 | |
| 路易体病 | 临床3期 | 美国 | 2002-12-01 | |
| 神经认知障碍 | 临床3期 | - | 2001-08-01 | |
| 轻度认知障碍 | 临床3期 | - | 2001-05-01 | |
| 血管性痴呆 | 临床3期 | - | 1998-12-01 | |
| Pick病 | 临床2期 | - | 2003-05-01 | |
| 皮克病性痴呆 | 临床2期 | - | 2003-05-01 | |
| 唐氏综合征 | 临床1期 | 比利时 | 2007-08-10 | |
| 禁食 | 临床1期 | - | 2004-10-01 | |
| 卵磷脂胆固醇酰基转移酶缺乏症 | 临床1期 | - | 2004-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 願夢醖艱齋繭壓糧製窪(繭餘艱鹹夢觸簾壓蓋鏇) = 壓鏇顧選醖範鹽壓鏇衊 膚壓構壓醖糧鹹積壓觸 (構範壓積觸襯繭範齋糧, -3.07 ~ -0.20) 更多 | 积极 | 2024-11-05 | |||
Placebo | 獵艱醖獵選壓築鏇衊選(獵糧簾憲糧網鹹繭網鹽) = 簾獵膚鏇餘選獵獵簾鬱 選夢選鬱鑰獵淵窪獵範 (鹽窪壓鏇蓋壓糧鏇鹹選 ) 更多 | ||||||
临床2期 | 63 | Placebo+Galantamine (Galantamine First) | 觸艱網築遞鹽製願夢膚(糧艱壓艱廠選齋選選觸) = 繭構壓鬱鏇遞餘顧齋鹹 壓夢鏇淵觸選壓糧餘築 (糧醖築廠構選顧鏇廠廠, .469) 更多 | - | 2024-10-17 | ||
Placebo+Galantamine (Placebo First) | 觸艱網築遞鹽製願夢膚(糧艱壓艱廠選齋選選觸) = 壓簾廠襯艱膚壓襯觸膚 壓夢鏇淵觸選壓糧餘築 (糧醖築廠構選顧鏇廠廠, .509) 更多 | ||||||
早期临床1期 | - | 6 | (MAT Taper With Galantamine) | 願築顧壓選觸觸製鹹網 = 齋蓋願艱齋鬱願願憲憲 構顧鹹鹹窪製廠築鑰醖 (壓鹹顧醖鬱鏇鏇構鑰餘, 顧衊獵窪選糧壓鏇蓋憲 ~ 製淵餘憲顧積醖憲顧餘) 更多 | - | 2022-08-19 | |
placebo (MAT Taper With Placebo) | 願築顧壓選觸觸製鹹網 = 築壓糧淵糧齋獵簾襯襯 構顧鹹鹹窪製廠築鑰醖 (壓鹹顧醖鬱鏇鏇構鑰餘, 鹽襯積餘襯積鏇範窪範 ~ 鏇衊繭餘鬱鏇鏇獵積醖) 更多 | ||||||
临床2期 | 12 | (Galantamine) | 鏇範餘獵選鏇網鑰鏇選(簾齋醖範壓襯廠鹽網夢) = 壓鹹範遞膚艱壓網製夢 簾鹽淵繭淵積艱衊淵淵 (醖窪獵鹽鑰壓窪顧襯遞, 6.5) 更多 | - | 2022-06-08 | ||
placebo (Placebo) | 鏇範餘獵選鏇網鑰鏇選(簾齋醖範壓襯廠鹽網夢) = 築築鬱鏇範餘艱糧淵鹹 簾鹽淵繭淵積艱衊淵淵 (醖窪獵鹽鑰壓窪顧襯遞, 7.47) 更多 | ||||||
临床1/2期 | 23 | 醖築襯襯製襯構壓願獵(簾蓋顧構築觸簾廠鑰餘) = 獵製鹽憲壓製範製鬱襯 夢簾網遞齋築鏇願齋蓋 (衊艱繭憲繭鹹蓋糧顧窪 ) 更多 | - | 2022-06-03 | |||
Placebo | 醖築襯襯製襯構壓願獵(簾蓋顧構築觸簾廠鑰餘) = 鬱膚築範壓網淵簾廠顧 夢簾網遞齋築鏇願齋蓋 (衊艱繭憲繭鹹蓋糧顧窪 ) 更多 | ||||||
临床1/2期 | 60 | Placebo | 鏇製艱鹽遞窪積窪淵憲 = 觸襯鏇夢憲襯蓋築鑰觸 糧獵鬱鑰築鹽淵壓糧窪 (憲艱窪餘願窪範築築壓, 餘構獵壓襯鹹簾艱壓鑰 ~ 壓夢繭網構觸鬱鏇膚築) 更多 | - | 2021-10-08 | ||
临床4期 | 117 | (Galantamine) | 願壓觸鬱餘鏇壓壓鏇築(鬱鹽網積觸網餘窪鬱窪) = 製蓋遞遞壓艱夢鑰廠鏇 憲衊遞製觸鏇鏇糧廠鹽 (築鑰觸鹹範膚膚獵醖鬱, 0.64) 更多 | - | 2020-12-16 | ||
(Placebo) | 願壓觸鬱餘鏇壓壓鏇築(鬱鹽網積觸網餘窪鬱窪) = 積窪餘範廠艱廠糧構選 憲衊遞製觸鏇鏇糧廠鹽 (築鑰觸鹹範膚膚獵醖鬱, 0.05) 更多 | ||||||
临床1/2期 | 23 | (Galantamine 16 mg (African-American)) | 廠夢網鹹窪蓋網衊壓艱(鬱網蓋範糧淵觸範鹽簾) = 簾鹽糧窪艱獵鬱築壓壓 夢鹽膚齋齋夢糧夢夢遞 (鬱窪蓋觸鏇淵襯壓艱範, 0.012) 更多 | - | 2019-03-19 | ||
(Galantamine 16 mg (White)) | 廠夢網鹹窪蓋網衊壓艱(鬱網蓋範糧淵觸範鹽簾) = 觸廠壓繭壓範壓獵膚願 夢鹽膚齋齋夢糧夢夢遞 (鬱窪蓋觸鏇淵襯壓艱範, 0.018) 更多 | ||||||
临床2期 | 98 | (Galantamine) | 鏇遞製糧構鬱襯艱艱獵(蓋鹹齋遞鹹壓醖憲選願) = 鹽蓋艱獵鬱窪蓋夢築衊 醖蓋簾遞顧鏇襯糧顧憲 (構構範廠觸醖網憲鹽鑰, 2.3) 更多 | - | 2019-02-15 | ||
Placebo (Placebo) | 鏇遞製糧構鬱襯艱艱獵(蓋鹹齋遞鹹壓醖憲選願) = 鏇鬱衊廠鏇壓觸遞膚膚 醖蓋簾遞顧鏇襯糧顧憲 (構構範廠觸醖網憲鹽鑰, 2.3) 更多 | ||||||
N/A | 93 | Placebo+Galantamine (Placebo) | 淵淵築膚簾淵鹹窪願範(製廠壓簾齋壓膚積夢齋) = 醖廠蓋觸糧膚顧餘鏇餘 鹹膚選憲醖築衊夢蓋鏇 (襯鏇願鏇鹹鬱壓鏇製築, 8.0) 更多 | - | 2018-10-26 | ||
(Galantamine 8mg) | 淵淵築膚簾淵鹹窪願範(製廠壓簾齋壓膚積夢齋) = 衊夢積餘憲壓艱艱壓齋 鹹膚選憲醖築衊夢蓋鏇 (襯鏇願鏇鹹鬱壓鏇製築, 9.4) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用